Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Programme
Postgraduate Teaching
Industry
Supporters
CME Accreditation
Congress Resources
UEG Week on-demand
Future UEG Weeks
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Start-up Grant
Research Prize
Research Fellowship
Research Webinars
Research Projects
HoloSurge
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
How to develop guidelines
Guideline Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Support
Start-up Grant
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Session
IBD: We treat them all - but how? (Posters)
PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY
IBD: We treat them all - but how? (Posters)
et al.
METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN TARGET COLONIC MUCOSA, AND WHITE BLOOD CELLS COMPARED TO NON-TARGET RED BLOOD CELLS OF PATIENTS WITH CROHN’S DISEASE
IBD: We treat them all - but how? (Posters)
et al.
REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN
IBD: We treat them all - but how? (Posters)
et al.
TIME TO EFFECT OF BIOLOGICS AND SMALL MOLECULES IN MODERATELY TO SEVERELY ACTIVE LUMINAL CROHN’S DISEASE – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
IBD: We treat them all - but how? (Posters)
et al.
THIOPURINE SHUNTING IN INFLAMMATORY BOWEL DISEASE PREGNANCIES INCREASES THE RISK OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY AND CAN BE MANAGED WITH SPLIT-DOSING: A PICCOLO-X STUDY
IBD: We treat them all - but how? (Posters)
et al.
KNOW NOCEBO: PREDICTING PATIENT OUTCOMES IN A 32-MONTH ADALIMUMAB BIOSIMILAR SWITCH STUDY
IBD: We treat them all - but how? (Posters)
et al.
EFFECT OF MILD OR MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF OZANIMOD
IBD: We treat them all - but how? (Posters)
et al.
CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
IBD: We treat them all - but how? (Posters)
et al.
EARLY CONCOMITANT IMMUNOMODULATOR TREATMENT PROVIDES ADDITIONAL BENEFIT IN INFLIXIMAB TREATED PEDIATRIC IBD PATIENTS DESPITE PROACTIVE DRUG MONITORING: RETROSPECTIVE ANALYSIS OF A 10-YEAR REAL-LIFE COHORT
IBD: We treat them all - but how? (Posters)
et al.
DISTINCT EFFECT OF ANTI-TUMOR NECROSIS FACTOR-ALFA AND CONVENTIONAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS
IBD: We treat them all - but how? (Posters)
et al.
DISTINCT EFFECT OF ANTI-TUMOR NECROSIS FACTOR-ALFA AND CONVENTIONAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS
REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN
TIME TO EFFECT OF BIOLOGICS AND SMALL MOLECULES IN MODERATELY TO SEVERELY ACTIVE LUMINAL CROHN’S DISEASE – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
KNOW NOCEBO: PREDICTING PATIENT OUTCOMES IN A 32-MONTH ADALIMUMAB BIOSIMILAR SWITCH STUDY
CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
EARLY CONCOMITANT IMMUNOMODULATOR TREATMENT PROVIDES ADDITIONAL BENEFIT IN INFLIXIMAB TREATED PEDIATRIC IBD PATIENTS DESPITE PROACTIVE DRUG MONITORING: RETROSPECTIVE ANALYSIS OF A 10-YEAR REAL-LIFE COHORT
PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY
METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN TARGET COLONIC MUCOSA, AND WHITE BLOOD CELLS COMPARED TO NON-TARGET RED BLOOD CELLS OF PATIENTS WITH CROHN’S DISEASE
THIOPURINE SHUNTING IN INFLAMMATORY BOWEL DISEASE PREGNANCIES INCREASES THE RISK OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY AND CAN BE MANAGED WITH SPLIT-DOSING: A PICCOLO-X STUDY
EFFECT OF MILD OR MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF OZANIMOD
Item 1 - 20 / 20
1
Chat with us
, powered by
LiveChat